Clinical Trial Update: Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. [Phase 4]

View source ↗

Summary

Phase 4 pharmacoeconomic analysis comparing meropenem as first-line therapy to standard antibiotics in seriously infected secondary nosocomial sepsis patients; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Meropenem (Meropenem)

Snippet

Sponsor: Pfizer | Conditions: Sepsis | Phase 4 | Status: COMPLETED